Stage I Testicular Germ Cell Tumors

被引:1
作者
Flechon, A. [1 ]
Mottet, N. [2 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69337 Lyon 08, France
[2] CHU St Etienne, Hop Nord, Serv Urol, F-42055 St Etienne 02, France
关键词
Testicular cancer; Seminoma; Nonseminomatous tumour; Stage I; ADJUVANT TREATMENT; RANDOMIZED-TRIAL; CANCER; SEMINOMA; RISK; TESTIS; SURVEILLANCE; TOMOGRAPHY; MANAGEMENT; RELAPSE;
D O I
10.1007/s10269-014-2384-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
State I testicular germ cell tumors are actually the most frequent ones, with a cure rate approaching 99%, whatever the histology or the chosen treatment. After orchidectomy it is defined by a normal thoraco-abdomino-pelvic CT scan and a normalized tumor marker, which depends on the initial level and the half-life. The PET CT has no place in the treatment. In the non-seminoma germ cell tumors, the presence of lymphovascular emboli defines a group with a high relapse rate, where an adjuvant chemotherapy with 2 courses of BEP is advised. Patients without emboli are preferably watched. A staging retroperitoneal node dissection has a marginal place. Regarding seminoma, no clear stratification factor is available. Lombo-aortic radiotherapy has been replaced by surveillance as standard treatment, while one single course of carboplatin (AUC 7) is an option. The strict implementation of the follow-up guidelines is mandatory to achieve the expected cure rate.
引用
收藏
页码:154 / 160
页数:7
相关论文
共 29 条
[1]  
ALBERS P, 2013, EAU GUIDELINES
[2]   Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German testicular cancer study group [J].
Albers, Peter ;
Siener, Roswitha ;
Krege, Susanne ;
Schmelz, Hans-Uwe ;
Dieckmann, Klaus-Peter ;
Heidenreich, Axel ;
Kwasny, Peter ;
Pechoel, Maik ;
Lehmann, Jan ;
Kliesch, Sabine ;
Koehrmann, Kai-Uwe ;
Fimmers, Rolf ;
Weissbach, Lothar ;
Loy, Volker ;
Wittekind, Christian ;
Hartmann, Michael .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :2966-2972
[3]   Risk-adapted management for patients with clinical stage I seminoma:: The second Spanish germ cell cancer cooperative group study [J].
Aparicio, J ;
Germà, JR ;
del Muro, XG ;
Maroto, P ;
Arranz, JA ;
Sáenz, A ;
Barnadas, A ;
Dorca, J ;
Gumà, J ;
Olmos, D ;
Bastús, R ;
Carles, J ;
Almenar, D ;
Sánchez, M ;
Paz-Ares, L ;
Satrústegui, JJ ;
Mellado, B ;
Balil, A ;
López-Brea, M ;
Sánchez, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8717-8723
[4]  
CAMPARO P, 2006, PATHOLOGIE TESTICULE, P92
[5]   Contemporary Management of Stage I and Stage II Seminoma [J].
Chung, P. ;
Sridharan, S. ;
Jewett, M. ;
Bedard, P. ;
Atenafu, E. ;
Moore, M. ;
Sweet, J. ;
O'Malley, M. ;
Anson-Cartwright, L. ;
Warde, P. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02) :S84-S85
[6]   Stage I Seminoma: Adjuvant Treatment is Effective but is it Necessary? [J].
Chung, Peter ;
Warde, Padraig .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (03)
[7]  
De Santis M, 2010, CANCER OF THE TESTIS, P75, DOI 10.1007/978-1-84800-370-5_4
[8]   Adjuvant treatment of clinical stage I seminoma:: Is a single course of carboplatin sufficient? [J].
Dieckmann, KP ;
Brüggeboes, B ;
Pichlmeier, U ;
Küster, J ;
Müllerleile, U ;
Bartels, H .
UROLOGY, 2000, 55 (01) :102-106
[9]   NERVE-SPARING RETROPERITONEAL LYMPHADENECTOMY WITH PRESERVATION OF EJACULATION [J].
DONOHUE, JP ;
FOSTER, RS ;
ROWLAND, RG ;
BIHRLE, R ;
JONES, J ;
GEIER, G ;
JEWETT, MAS .
JOURNAL OF UROLOGY, 1990, 144 (02) :287-292
[10]   TREATMENT OPTIONS IN CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - A WAGER ON THE FUTURE - A REVIEW [J].
DROZ, JP ;
VANOOSTEROM, AT .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) :1038-1044